RS7 antibodies

Patent metadata

Field	Value
Publication number	US-9833511-B2
Application number	US-201414259469-A
Country	US
Kind code	B2
Filing date	Apr 23, 2014
Priority date	Mar 1, 2002
Publication date	Dec 5, 2017
Grant date	Dec 5, 2017

Abstract

This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

First claim

What is claimed is:

1. A method of treating a cancer that expresses TROP-2 (EGP-1) comprising administering a chimeric, humanized or human anti-TROP-2 antibody to a human subject with a TROP-2 positive cancer, wherein the anti-TROP-2 antibody comprises the light chain complementarity determining region (CDR) sequences CDR1 (KASQDVSIAVA, SEQ ID NO:28), CDR2 (SASYRYT, SEQ ID NO:29), and CDR3 (QQHYITPLT, SEQ ID NO:30) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:31), CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:32), and CDR3 (GGFGSSYWYFDV, SEQ ID NO:33), wherein the antibody is conjugated to an anti-cancer drug that is delivered to the Trop-2 expressing cancer.

2. The method of claim 1 , wherein the anti-TROP-2 has a heavy chain allotype G1m3, a heavy chain isoallotype nG1m1,2 and a light chain allotype Km3.

3. The method of claim 1 , wherein the cancer is selected from the group consisting of breast, ovarian, uterine, lung, colon, stomach, bladder, and head-and-neck cancer.

4. The method of claim 1 , wherein the drug is selected from the group consisting of a nitrogen mustard, ethyleneimine derivative, alkyl sulfonate, nitrosourea, triazene, folic acid analog, anthracycline, taxane, COX-2 inhibitor, tyrosine kinase inhibitor, pyrimidine analog, purine analog, antibiotic, epipodophyllotoxin, platinum coordination complex, vinca alkaloid, substituted urea, methyl hydrazine derivative, adrenocorticol suppressant, antagonist, endostatin, paclitaxel, camptothecin, doxorubicin, doxorubicin analog, methotrexate, and CPT-11.

5. The method of claim 1 , wherein the anti-TROP-2 antibody is a humanized antibody comprising human framework region (FR) and constant region sequences, and further comprising one or more FR amino acid substitutions selected from the group consisting of heavy chain residues K38, K46, A68, and F91 and light chain residues S20, D60, V85 and A100.

Assignees

• Immunomedics Inc

Inventors

• Govindan Serengulam V
• Qu Zhengxing
• Hansen Hans J
• Goldenberg David M

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title